$VBIO News

Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options

Valion Bio Confirms Receipt Of Proposed Acquisition Offers For Its Velocity Bioworks; Terms Undisclosed

Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value

Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone

Valion Bio's Velocity Biowork Subsidiary Completes Initial Feasibility Evaluation Of LarmorBio's BioScan-NMR Platform

With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge

Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers

Valion Bio Completes Oral Mucosal Entolimod Formulation, Opening Potential Needle-Free Development Pathway

Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity

Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions

Valion Bio Appoints Dean Zikria Interim CEO, Thomas Jensen As Board Chair

Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Valion Bio Regains NASDAQ Compliance

Valion Bio Announces Changes to Management and Board of Directors

Valion Bio Appoints Lisa Wolf To Expanded Roles Of President, COO, Effective Immediately

Valion Bio Announces Reverse Stock Split

Valion Bio Announces 1-For-25 Reverse Stock Split, Effective Aug. 31

Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase

Valion Bio Advances Government-Funded Entolimod Radiation Injury Studies With Data Expected in Early Fall

Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury